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1 
Abstract 1 
Aim: Acetaminophen is a commonly used medicine for pain relief and emerging evidence 2 
suggests that it may improve endurance exercise performance. This study investigated some 3 
of the physiological mechanisms by which acute acetaminophen ingestion might blunt 4 
muscle fatigue development. Methods: Thirteen active males completed 60 × 3 s maximum 5 
voluntary contractions (MVC) of the knee extensors with each contraction separated by a 2 s 6 
passive recovery period.  This protocol was completed 60 min after ingesting 1 g of 7 
maltodextrin (placebo) or 1 g of acetaminophen on two separate visits.  Peripheral nerve 8 
stimulation was administered every 6
th
 contraction for assessment of neuromuscular fatigue 9 
development, with the critical torque (CT), which reflects the maximal sustainable rate of 10 
oxidative metabolism, taken as the mean torque over the last 12 contractions. Surface 11 
electromyography was recorded continuously as a measure of muscle activation.  Results: 12 
Mean torque (61 ± 11 vs. 58 ± 14 % pre-exercise MVC) and CT (44 ± 13 vs. 40 ± 15 % pre-13 
exercise MVC) were greater in the acetaminophen trial compared to placebo (both P<0.05). 14 
Voluntary activation and potentiated twitch declined at a similar rate in both conditions 15 
(P>0.05). However, the decline in electromyography amplitude was attenuated in the 16 
acetaminophen trial, with electromyography amplitude being greater compared to placebo 17 
from 210 s onwards (P<0.05). Conclusion: These findings indicate that acute acetaminophen 18 
ingestion might be ergogenic by increasing CT and preserving muscle activation during high-19 
intensity exercise.  20 
 21 
Key words: Analgesic; critical torque; electromyography; neuromuscular fatigue; single leg 22 
exercise  23 
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Abbreviations 24 
ACT 
 
Acetaminophen  (paracetamol) 
CT 
 
Critical torque (i.e., asymptote of the P-Tlim relationship) 
EMG 
 
Electromyography  
EMGRMS 
 
EMG amplitude using root mean square method  
M-wave 
 
M-wave amplitude 
Mmax 
 
Maximal m-wave amplitude  
MVC Maximal voluntary contraction 
 
PL 
 
Placebo  
pTw 
 
Potentiated twitch 
RMS 
 
Root mean square 
sTw 
 
Superimposed twitch (onto an MVC) 
VA Voluntary activation (%) 
 
W′ 
 
Curvature constant of the hyperbolic Torque-Tlim relationship 
25 
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Introduction 26 
Neuromuscular fatigue is defined as a decrease in skeletal muscle force production capacity 27 
(Gandevia, 2001). This neuromuscular fatigue development can arise from physiological 28 
perturbations within the central nervous system, termed central fatigue, or within, or distal to, 29 
the neuromuscular junction, termed peripheral fatigue (Gandevia, 2001). Exercise-induced 30 
fatigue is a complex, multi-factorial process, the physiological bases of which are still widely 31 
debated (Enoka & Duchateau, 2008; Gandevia, 2001; Hureau et al. 2016; Place et al. 2010; 32 
Taylor et al. 2016).  Indeed, recent research suggests that peripheral fatigue and central 33 
fatigue develop inter-dependently and are likely to interact in a coordinated manner to 34 
determine neuromuscular fatigue development (Hureau et al. 2016).  35 
 36 
Following the onset of muscle contractions, group III and IV afferents discharge in response 37 
to mechanical and metabolic stimuli, contributing to the sensation of muscle pain during 38 
exercise (O’Connor & Cook, 1999; McCord and Kaufmann, 2010; Pollak et al. 2014). Group 39 
III/IV muscle afferent feedback, and the associated sensation of pain, appears to play a role in 40 
neuromuscular fatigue development through modulating both central and peripheral fatigue. 41 
Indeed, when the ascending projection of group III and IV muscle afferents is attenuated via 42 
intrathecal fentanyl administration, central motor drive is increased (as inferred via EMG) 43 
and peripheral fatigue development is expedited (Amann et al. 2009, 2011; Blain et al. 2016). 44 
Therefore, interventions that can modulate skeletal muscle pain sensation have the potential 45 
to impact muscle activation and exercise-induced fatigue development. 46 
 47 
Acetaminophen (ACT; or paracetamol) is a commonly used non-prescription pain reliever 48 
which is considered one of the safest non-opioid analgesics at therapeutic doses (Toussaint et 49 
al. 2010). Acute ACT consumption has been shown to improve exercise performance 50 
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concomitant with a lower pain sensation (Foster et al. 2014; Mauger et al. 2010). The 51 
mechanisms that underlie the analgesic effect of ACT are not completely understood but are 52 
considered to be predominantly mediated by central factors (Anderson, 2008; Graham et al. 53 
2013; Smith, 2009; Toussaint et al. 2010). Conventionally, the analgesic effect of ACT has 54 
been attributed to the inhibition of cyclooxygenase enzymes, which stimulate nociceptor 55 
discharge through the synthesis of prostaglandins (Graham et al. 2013; Jóźwiak-Bębenista 56 
and Nowak, 2014). There is also evidence that the analgesic effect of ACT is linked to 57 
potentiation of descending serotoninergic pathways (Pickering et al. 2006, 2008), and to 58 
modulation of opioid and cannabinoid receptors (Graham et al. 2013). These mechanisms 59 
likely interact to lower pain sensation after acute ACT ingestion by increasing the 60 
nocioceptive stimuli required to evoke a given pain sensation. Although ACT ingestion has 61 
been reported to increase resting cortico-spinal excitability, as inferred from an increased 62 
motor evoked potential amplitude (Mauger & Hopker, 2013), the neuromuscular bases for 63 
blunted exercise-induced fatigue development following ACT ingestion have yet to be 64 
investigated.   65 
 66 
In addition to altering pain sensation and neuromuscular function, ACT ingestion might 67 
attenuate fatigue development and enhance performance by modulating aspects of the power 68 
or torque-duration relationship. The asymptote of the hyperbolic torque-duration relationship 69 
is termed the critical torque (CT) and can be estimated from the mean torque produced over 70 
the last 12 maximum voluntary contractions (MVCs) of a 60 MVC knee extension protocol 71 
(Burnley, 2009). The CT reflects the maximal sustainable rate of oxidative metabolism (Jones 72 
et al. 2008; Jones et al. 2011 for review) and represents a critical threshold for neuromuscular 73 
fatigue development (Burnley et al. 2012).  The curvature constant of the torque-duration 74 
hyperbola is termed the W′ and represents a fixed amount of torque-impulse (surrogate 75 
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measure of ‘total work’) that can be completed above CT (Burnley and Jones, 2016; Jones et 76 
al. 2008; Poole et al. 1988). Together, CT (or critical power, critical speed for other forms of 77 
exercise) and W′ (or its equivalent) can be used to accurately predict exercise performance 78 
(Black et al. 2014, Burnley et al. 2012).  An intervention that enhances high-intensity 79 
exercise tolerance or performance, or attenuates fatigue development, would be expected to 80 
enhance CT or W′ (or their exercise-modality-specific equivalents) For example, critical 81 
power, but not W′, is increased following endurance training concomitant with improved 82 
endurance exercise performance (Vanhatalo et al. 2008). Therefore, the reported 83 
improvement in exercise performance with acute ACT ingestion (Foster et al. 2014; Mauger 84 
et al. 2010, 2014) would be expected to be linked to improvements in CT and/or W′, but this 85 
has yet to be investigated.   86 
 87 
The purpose of this study was to test the hypotheses that, compared to placebo, acute 88 
consumption of 1 g ACT would reduce the rate of neuromuscular fatigue development, and 89 
increase total impulse (torque-time integral), CT and muscle activation during a 5 min single-90 
leg intermittent MVC test. 91 
 92 
Materials and methods 93 
Participants 94 
Thirteen healthy male volunteers (mean ± SD: age 31 ± 7 years, height 1.76 ± 0.08 m, body 95 
mass 75 ± 11 kg) provided written, informed consent to participate in the present study, 96 
which was approved by the Ethics Committee of Sport and Health Sciences (University of 97 
Exeter). After being informed of the experimental procedures and associated risks, all 98 
participants completed a medical health questionnaire to ensure it was safe to consume ACT 99 
prior to performing exhaustive exercise. Subjects were not consumers of any ‘pain relief’ 100 
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medication (prescription or non-prescription) over the course of the study. None of the 101 
subjects had a history of motor or neurological disorders.  102 
 103 
Experimental Design 104 
Subjects visited the laboratory on three occasions over a 3- to 4-week period with all tests 105 
separated by at least 1 week and conducted at a similar time of day (± 90 min) to limit 106 
changes in quadriceps strength and to account for diurnal variations in neuromuscular 107 
excitability. The first laboratory visit was used to familiarise subjects to the measurements 108 
and experimental protocol described below. During these sessions, the settings and placement 109 
of the dynamometer and electromyography (EMG) and peripheral nerve stimulation 110 
electrodes were recorded for each subject. Subsequently, subjects performed the fatiguing 111 
protocol under two conditions (see ‘Experimental Protocol’): placebo (PL) and ACT.  112 
 113 
Experimental Protocol  114 
Subjects completed a preliminary trial for familiarisation to the measurement techniques and 115 
experimental protocol. An isokinetic dynamometer (Biodex System 3, Shirley, NY, USA) 116 
was used in all tests and adjusted so that the axis of rotation of the lever arm was in line with 117 
the lateral epicondyle of the right femur. Subjects were seated with the hip and knee joints at 118 
relative angles of 155° and 90°, respectively. The remainder of the chair settings were 119 
recorded and replicated in all subsequent trials to ensure an identical body position was 120 
assumed throughout the experimental trials. The semi-supine position was employed as it 121 
permitted better access to the superficial femoral nerve for peripheral nerve stimulation as 122 
verified during pilot testing. Inelastic padded Velcro straps were fastened at the ankle, 123 
quadriceps, hip and shoulders to maintain a stable body position. The procedures adopted 124 
during the familiarisation trial were replicated in all experimental trials.  125 
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 126 
The trials on visits 2 and 3 were completed in a double-blind, randomised fashion using a 127 
cross-over experimental design. Prior to each visit, subjects were required to refrain from 128 
caffeine (for at least 12 h), strenuous exercise and alcohol (for at least 24 h), analgesics and 129 
any form of anti-inflammatory drug (for the duration of the experimental trial) and to arrive 130 
in a fully rested, hydrated state. Subjects were instructed to maintain their usual diet and 131 
exercise regime during the study. 1 g of maltodextrin (placebo) or 1 g of acetaminophen was 132 
ingested orally, 60 minutes prior to the exercise bout such that the start of the exercise trial 133 
was expected to coincide with attainment of the peak plasma [acetaminophen] (Anderson et 134 
al. 2008; Forrest, Clements & Prescott, 1982). Following oral ingestion, ACT is rapidly 135 
absorbed from the gastrointestinal tract and its bioavailability ranges from 70 to 90% 136 
(Forrest, Clements & Prescott, 1982). The trials started with a standardised isometric warm-137 
up routine (10 isometric contractions for 3 s at 50% of pre-exercise MVC as determined 138 
during familiarisation testing) and testing of the optimal EMG electrode, anode, and cathode 139 
placement and stimulation intensity for peripheral nerve stimulation. Neuromuscular function 140 
was assessed pre-trial, during and (< 10 s) post-trial.  Single peripheral nerve stimulation 141 
pulses were manually triggered at rest to determine pre-exercise neuromuscular function, 142 
namely the characteristics of the M-wave response (M-wave amplitude; Mmax) to supra-143 
maximal nerve stimulation, contractility of the muscle (i.e. maximal rate of force 144 
development, half relaxation time and contraction time), voluntary activation (VA) and 145 
potentiated twitch force (pTw). During maximal voluntary contractions (MVCs), peripheral 146 
nerve stimulation pulses were triggered to occur as soon as a peak torque was achieved 147 
(typically 1.5 s into a 3 s contraction), each separated by a 40 s rest. The stimuli were also 148 
delivered 1-2 s after the cessation of the contraction to provide a resting pTw. Identical 149 
9 
 
measurements were repeated as soon as possible (<10 s) after the fatiguing exercise to 150 
determine post-exercise neuromuscular function (see Fig. 1).  151 
 152 
The intermittent isometric contraction protocol used in this study had a similar design to that 153 
presented by Burnley (2009). The protocol consisted of repeated brief MVCs (3 s contraction, 154 
2 s rest), timed via a visual prompt to ‘go’ and ‘relax’ (separate to the torque output screen), 155 
accompanied by the same verbal instructions from the experimenter. The protocol was 156 
terminated when the subjects completed the 60
th
 MVC. Every 6
th
 contraction was 157 
accompanied by peripheral nerve stimulation during and post MVC (as described for pre- and 158 
post-trial measurements). Subjects were not given a visual representation of the torque 159 
produced during each MVC or made aware of the number of MVCs elapsed during the 160 
protocol. Subjects were instructed to continue to perform maximal contractions throughout. 161 
The coefficient of variation for MVC performance (mean torque through 60 MVCs) and 162 
electromyography root mean square (EMGRMS) amplitude using this experimental set up was 163 
2.9% and 4.8%, respectively as calculated during pilot testing. 164 
 165 
Measurements 166 
Torque 167 
Knee-extensor torque from the Biodex dynamometer was sampled at 1,000 Hz and low-pass 168 
filtered at 40 Hz, before being displayed on a wide screen monitor using Spike2 (CED, 169 
Cambridge, UK).  Torque was expressed throughout as a percentage (%) of pre-exercise 170 
MVC.  171 
 172 
Electromyography  173 
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Surface EMG activity was recorded from vastus lateralis, vastus medialis and rectus femoris 174 
of the quadriceps and biceps femoris of the hamstring of the right leg using active bipolar bar 175 
electrodes single differential configuration (DE2.1, DelSys Inc, Boston, MA, USA). The 176 
electrodes were placed over the respective muscle bellies (SENIAM guidelines). Double-177 
sided adhesive tape and a hypoallergenic medical tape were used to ensure the EMG sensor 178 
stability for recording electrodes. The skin area underneath each EMG electrode was shaved, 179 
then exfoliated and cleaned with alcohol to minimise the skin impedance. The EMG and 180 
torque signals were pre-amplified (1,000 x), band-pass filtered (20–450 Hz, Bagnoli-8, 181 
DelSys Inc, Boston, MA, USA), and then transferred to a computer with a sampling 182 
frequency of 2 kHz and high-pass filtered at 10 Hz. EMG and torque data were recorded 183 
continuously and digitised synchronously with 16 bit resolution via an A/D converter (±5 V 184 
range, CED 1401 power, Cambridge, UK). The electrodes were used to record: 1) evoked 185 
muscle action potentials (peak-to-peak amplitude of the M-wave); and 2) EMG to estimate 186 
muscle activity and the output of spinal motoneurons (motor unit recruitment and firing 187 
frequency). EMG was average rectified using the root mean square method (EMGRMS). 188 
EMGRMS was then normalised to the pre-exercise maximum (or maximal EMG signal) and 189 
the local M-wave amplitude (closest measure of the M-wave to the MVC) in order to exclude 190 
any changes to the EMG trace to changes in local excitability. The ground electrode was 191 
placed over the patella of the right leg.  192 
 193 
Peripheral Nerve Stimulation 194 
Electrical stimulation was applied by a constant current stimulator (Digitimer Stimulator 195 
DS7, Digitimer, UK). M-waves were elicited by supramaximal percutaneous electrical 196 
stimulation of the femoral nerve (200 µs duration). The cathode was placed over the femoral 197 
nerve in the inguinal fossa, approximately 3–5 cm below the inguinal ligament in the femoral 198 
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triangle. Once the M-wave was elicited, the maximum amplitude (peak-to-peak) of the M-199 
wave was determined (Mmax) for the vastus lateralis and vastus medialis. To determine the 200 
stimulation intensity (current), single stimuli were delivered in 20 mA step-wise increments 201 
from 100 mA until a plateau in quadriceps pTw and M-wave were observed. To ensure a 202 
supramaximal response, the current was increased by an additional 30% (mean ± SD current 203 
= 194 ± 81 mA; Burke, 2002; Goodall et al. 2010; Neyroud et al. 2014). The average Mmax 204 
was obtained from 3 stimuli, with ~8-10 s separating each pulse at rest. Peak torque, maximal 205 
rate of force development, half relaxation time and contraction time were analysed for all 206 
pTw.  207 
 208 
Data Analyses 209 
Data were analysed using a custom written script developed in Spike2 software (CED, 210 
Cambridge, UK). Mean torque for each 3 s contraction was determined for all tests as the 211 
mean value over a 1 s period which approximated the plateau level of the highest torque (i.e. 212 
500 ms before and after the peak torque). The pTw was calculated as the peak torque 213 
achieved following the single pulse delivered 1 s post-MVC. The twitch torque superimposed 214 
onto the peak force production of the MVC (sTw) was calculated as the increment in torque 215 
immediately following the pulse during MVCs. The torque impulse was calculated as the area 216 
under the torque-time curve by accumulating the time integral of each MVC (3 s) by the 217 
difference in torque between MVCs. The end-test torque (i.e. CT) during the 60 MVC test 218 
was defined as the mean of the last 12 contractions (i.e. the last 60 s; Burnley, 2009). The Wʹ 219 
was calculated as the area above the CT from the torque-time curve (i.e. impulse above CT). 220 
Central fatigue was assessed as the maximal voluntary activation of the motoneuron pool 221 
(VA, %), calculated using the interpolated twitch method from peripheral nerve stimulation 222 
(Merton, 1954). Specifically, the increment in torque evoked during the MVCs was expressed 223 
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as a fraction of the amplitude of the potentiated twitch produced with the same stimulus in the 224 
relaxed muscle post MVC. The level of voluntary drive was then quantified as a percentage: 225 
[1 − evoked torque (superimposed on voluntary torque, sTw)/ (mean control evoked 226 
response, pTw) × 100] (i.e. Allen at al. 1998).  227 
 228 
The changes in maximal voluntary torque, pTw, VA and EMGRMS, were used to quantify 229 
peripheral fatigue and central fatigue. The maximal EMG was taken from the first MVC 230 
during the 60 MVC task and compared to the last MVC at task end. The neuromuscular 231 
parameters extracted from the three sets of maximal contractions completed post-exercise 232 
were tested for statistical differences between sets of contractions and then compared to the 233 
first set of MVCs completed pre-exercise (Froyd et al. 2013; Pageaux et al. 2015a; Doyle-234 
Baker et al. 2017). Neuromuscular function was also measured for each of the stimulated 235 
contractions during the exercise and normalised to the corresponding pre-exercise values at 236 
100% MVC. All neuromuscular parameters and torque were averaged across the protocol 237 
using 6 (30 s) bin averages.  238 
 239 
Statistics 240 
Paired-samples t-tests were used to compare the mean torque, total impulse, CT and Wʹ (i.e. 241 
impulse above CT) between ACT and PL conditions. In addition, paired samples t-tests were 242 
used to assess parameters of neuromuscular function at task end between trials including 243 
pTw, maximal rate of force development, half relaxation time and contraction time. The 244 
profiles of torque, VA, pTw and m-wave amplitude were analysed using two-way ANOVAs 245 
with repeated measures (using 12 contraction averages; i.e. 6 time points). Normalised 246 
EMGRMS were analysed using two-way ANOVAs with repeated measures using 30 s mean 247 
values (i.e. 10 time points). Where the ANOVA revealed a significant interaction effect, post-248 
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hoc tests were completed using a Bonferroni correction. For calculation of effect size, partial 249 
eta squared (η2) was used for omnibus tests. Cohen's d was used to calculate the effect size 250 
for paired t-tests and post-hoc comparisons. A t-test was also conducted on the differences in 251 
EMG and force production (torque) from task end (i.e. 300 s) to 150 s (mid-point) to assess 252 
the rate of change as the protocol progressed. All statistical tests were performed both on % 253 
change and raw data. Where sphericity was violated, a greenhouse-geisser correction factor 254 
was used. For all tests, results were considered statistically significant when P<0.05. Data are 255 
presented as means ± SD unless otherwise indicated. All statistical analyses were conducted 256 
using IBM SPSS Statistics version 23. 257 
 258 
Results 259 
The mean MVC torque achieved prior to the 60 MVC protocol was 232 ± 47 and 228 ± 48 260 
N.m for PL and ACT, respectively.  Voluntary activation of the knee extensors achieved 261 
during the preliminary MVCs was 88 ± 7% and 87 ± 5 for PL and ACT, respectively. 262 
Baseline MVC and VA were not different between conditions (P>0.05).  263 
 264 
60 MVC Performance 265 
The profile for mean torque across all subjects and a representative individual plot during 266 
each contraction for the 60 MVC protocol is shown in Fig. 2. During the PL trial, torque 267 
declined from a peak of 99 ± 3% MVC (relative to pre-exercise MVC) during the first 268 
contraction to 40 ± 15% MVC during the last 12 contractions (P<0.0001, η2=0.908; Table 1, 269 
Fig. 2). The mean torque (relative to pre-exercise MVC) achieved across the 60 MVCs was 270 
greater with ACT (61 ± 11%, 97.1 ± 23.2 N.m) compared to PL (58 ± 14%, 83.8 ± 22.7 N.m; 271 
P=0.030, d=0.656) and there was a significant interaction effect (time × condition; P=0.036, 272 
η2=0.260). Post-hoc tests revealed significant differences in torque between conditions at task 273 
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end (P=0.044, d =0.656) but at no other time-points (all P>0.084 and d<0.548). CT was 274 
higher with ACT compared to placebo (ACT: 44 ± 13 % vs. PL: 40 ± 15%, P=0.011, 275 
d=0.691), with no between-condition differences in Wʹ (PL: 6.97 ± 2.43, ACT: 6.91 ± 2.54 276 
N.m.s; P=0.879, d=0.026). Total impulse in the 60 MVC protocol was higher with ACT 277 
(24386 ± 3793 N.m.s) compared to PL (22055 ± 3885 N.m.s; P=0.006, d=0.973). As time 278 
progressed, the difference in force production between conditions increased as evidenced by 279 
a significant difference in rates of change between conditions (i.e. difference between 300 280 
and 150 s time points; P=0.035, d=0.696). The individual responses following ACT 281 
supplementation to the torque-impulse can be seen in Fig. 3. Table 2 illustrates the 282 
parameters of the 60 MVC test for PL and ACT for individual subjects and is available as an 283 
online supplement. 284 
 285 
Neuromuscular Function 286 
There was a main effect for time on pTw (Fig. 4a, P<0.001, η2=0.754), voluntary activation 287 
(Fig. 4b, P<0.001, η2=0.647) and m-wave amplitude (Fig. 4c, P=0.005, η2=0.281), which all 288 
declined as the protocol progressed. VA declined from 89 ± 8% to 59 ± 19% and from 88 ± 289 
5% to 62 ± 16% in the PL and ACT conditions (P<0.0001, Fig 3), respectively. However, 290 
there were no main condition effect on M-wave amplitude (P=0.733, η2=0.012), pTw 291 
(P=0.783, η2=0.032) or VA (P=0.841, η2=0.004) between the PL and ACT conditions (Fig. 292 
4c). Likewise, there was no significant interaction effect (i.e. time × condition) on M-wave 293 
amplitude (P=0.993, η2=0.009) or VA (P=0.387, η2=0.097). In addition pTw declined from 294 
68 ± 8 to 30 ± 20 N·m and from 71 ± 12 to 31 ± 23 N·m (both P<0.0001) for PL and ACT, 295 
respectively, but there was no significant difference in end-exercise pTw between conditions 296 
(P=0.763, d=0.047). There was also no significant difference in end-exercise maximal rate of 297 
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force development (P=0.181, d=0.383), half relaxation time (P=0.234, d=0.341) or 298 
contraction time (P=0.595, d=0.232) between conditions. 299 
 300 
Using 6 contraction (30-s) bin means, EMGRMS decreased from 99 ± 4% to 59 ± 17% in the 301 
PL trial (from first 6 to last 6 contractions; P<0.0001, η2=0.502; Fig. 5). This decline in 302 
EMGRMS was attenuated following ACT ingestion (100 ± 5 to 87 ± 28%), demonstrating a 303 
significant main effect of condition (P=0.033, η2=0.381) and an interaction effect (P=0.043, 304 
η2=0.229). The EMGRMS was elevated at 60 s (P=0.036, d=0.730), 90 s (P=0.020, d=0.835), 305 
210 s (P=0.070), 240 s (P=0.015, d=0.886), 270 s (P=0.019, d=0.844) and 300 s (P=0.001, 306 
d=1.306) in ACT compared to PL (Fig. 5). As time progressed, the difference in EMG 307 
amplitude between conditions increased as evidenced by a significant difference in rates of 308 
change between conditions (i.e. difference between 300 and 150 s time points; P=0.024, 309 
Cohen’s d=0.804).  310 
 311 
Discussion  312 
Consistent with our experimental hypotheses, the principal findings of this study were that 313 
acute ACT ingestion increased mean MVC torque, and increased CT and EMG amplitude 314 
during the latter stages of the 60 MVC protocol. These observations offer insights into the 315 
mechanisms by which ACT blunts fatigue development and suggest that the ergogenic effect 316 
of ACT ingestion may be linked to increases in CT and muscle activation during fatiguing 317 
skeletal muscle contractions.      318 
 319 
In the present study, fatigue development and some of its underpinning mechanisms were 320 
assessed during the completion of 60 MVCs of the knee-extensors using the protocol 321 
described by Burnley (2009). Consistent with Burnley (2009), torque and pTw declined by 322 
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60% and 30%, respectively, and VA declined to 59%, reflecting peripheral and central 323 
fatigue development. However, although neuromuscular fatigue was also manifest during the 324 
ACT trial, the acute ingestion of ACT increased the mean torque during the fatiguing 60 325 
MVC protocol by ~4% compared to the PL condition. This finding is in line with previous 326 
observations that acute ACT ingestion can improve performance during whole body exercise 327 
in humans (Foster et al. 2014; Mauger et al. 2010a).   328 
 329 
The attenuation of neuromuscular fatigue development following ACT ingestion was not 330 
accompanied by specific alterations in central fatigue (voluntary activation), peripheral 331 
fatigue (potentiated twitch, pTw) or peripheral neuromuscular excitability (M-wave) between 332 
the ACT and placebo trials.  However, while EMG declined across the 60 MVC protocol in 333 
both conditions, it declined to a lesser extent with ACT (declined to ~87 %) compared to 334 
PLA (declined to ~59%).  This observation suggests that improved muscle activation might 335 
have contributed to the ergogenic effect of ACT ingestion. This interpretation is strengthened 336 
by our observation of a positive correlation between the inter-trial changes in EMG and 337 
torque (r = 0.85). Although ACT ingestion has previously been reported to increase cortico-338 
spinal excitability at rest (Mauger & Hopker, 2013), the neuromuscular mechanisms for 339 
improved performance during exercise had not been explored in previous studies reporting an 340 
ergogenic effect of ACT ingestion (Foster et al. 2014; Mauger et al. 2010, 2014).  Therefore, 341 
by suggesting that ACT can improve muscle activation during repeated fatiguing skeletal 342 
muscle contractions, our findings extend previous observations by providing insight into the 343 
potential neuromuscular bases for the ergogenic effect of ACT ingestion.     344 
 345 
It is possible that the effect of ACT may be linked to a sub-conscious neuromuscular 346 
alteration during exercise via a reduction in the magnitude of muscle afferent feedback. 347 
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During exercise, ascending group III and IV muscle afferents discharge in response to 348 
noxious, metabolic and mechanical stimuli within the contracting skeletal muscles to regulate 349 
the sensation of pain, muscle activation and peripheral fatigue development (Amann et al. 350 
2009, 2011; Blain et al. 2016; Hureau et al. 2016; McCord and Kaufmann, 2010; Pollak et al. 351 
2014). When the magnitude of type III and IV muscle afferent feedback is reduced, 352 
performance is compromised and pacing strategy is adversely impacted (Amann et al. 2009, 353 
2011; Blain et al. 2016), despite enhanced muscle activation, as peripheral fatigue 354 
development is exacerbated. ACT administration, on the other hand, which seemingly acts 355 
predominantly through central processes to blunt pain sensation (Anderson, 2008; Graham et 356 
al. 2013; Smith, 2009; Toussaint et al. 2010), appears to have attenuated the decline in 357 
muscle activation without impacting peripheral fatigue development, culminating in blunted 358 
neuromuscular fatigue development in the current study. Taken together, these observations 359 
suggest that reducing, but not abolishing, pain sensation can attenuate neuromuscular fatigue 360 
development during exercise or that a higher magnitude of afferent feedback is needed to 361 
trigger a given pain sensation. The findings, whilst suggesting that improved maintenance of 362 
muscle activation might have contributed to the ergogenic effect of ACT ingestion, cannot 363 
differentiate between a sub-conscious alternation in neuromuscular control or a conscious 364 
ability to increase muscle recruitment via a reduction in pain sensation.  365 
 366 
The increased muscle activation in the latter stages of the ACT trial compared to the placebo 367 
trial was accompanied by a higher mean torque over the final 12 MVCs, and therefore a 368 
higher CT (Burnley, 2009). The CT is an important physiological threshold that is linked to 369 
neuromuscular fatigue development through influencing muscle metabolic homeostasis 370 
(Jones et al. 2008; Vanhatalo et al. 2016), systemic respiratory and acid-base profiles (Poole 371 
et al. 1988) and neuromuscular fatigue development (Burnley et al. 2012). During the 60 372 
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MVC protocol employed in the current study, there is a precipitous perturbation to skeletal 373 
muscle homeostasis, central and peripheral fatigue development, a decline in muscle 374 
activation and a hyperbolic reduction in torque that asymptotes at CT (Burnley, 2009; 375 
Burnley et al. 2010). By lowering pain sensation (Foster et al. 2014; Mauger et al. 2010), 376 
ACT might have permitted the attainment of a greater degree of intramuscular metabolic 377 
perturbation, thereby leading to improved exercise tolerance. However, since potentiated 378 
twitch was not different between the ACT and placebo trials, it appears that ACT ingestion 379 
did not result in greater peripheral fatigue development in this study. Instead, ACT ingestion 380 
enhanced muscle activation and increased CT over the latter stages of the 60 MVC protocol. 381 
Therefore, it is also possible that ACT ingestion lowered fatigue development through 382 
permitting greater muscle activation for a given degree of intramuscular metabolic 383 
perturbation.  384 
 385 
The blunted neuromuscular fatigue development in this study occurred in association with 386 
increased muscle activation.  However, it is surprising that the attenuation in neuromuscular 387 
fatigue development was not accompanied by changes in central (i.e. voluntary activation) or 388 
peripheral (i.e. potentiated twitch force) fatigue in this study. Indeed, since muscle activation 389 
and torque were increased, this might be expected to result in greater intramuscular metabolic 390 
perturbation and, by extension, greater peripheral fatigue development.  Although we cannot 391 
exclude the possibility that ACT enhanced systemic physiological responses or skeletal 392 
muscle efficiency to mitigate this potential for greater peripheral fatigue development, we are 393 
not aware of any published evidence to support such effects. 394 
 395 
Experimental Considerations  396 
19 
 
It is acknowledged that a limitation of the current study was that pain sensation were not 397 
directly assessed. Pain was not assessed due to the protocol requiring the completion of 60 398 
MVCs with a short (2 s) recovery period; asking subjects to rate pain sensation in this setting 399 
may have compromised their ability to focus on the exercise task and provide a true maximal 400 
effort during the experimental protocol. Previous studies have observed a higher power 401 
output for the same pain sensation, suggestive of a reduction in the sensation of pain during 402 
cycle ergometry exercise (Foster et al. 2014; Mauger et al. 2010). However, these studies 403 
used a higher ACT dose (1.5 g) and a different exercise modality (cycling) compared to the 404 
current study. Therefore, we are unable to draw conclusions regarding pain sensation with 405 
ACT in the current study. It should also be acknowledged that in the face of a relatively small 406 
(~4%) improvement in torque, it is possible that the central and peripheral fatigue 407 
measurements in our study were not sensitive enough to detect small defects in central 408 
nervous system and peripheral muscle function. Moreover, while ACT increased EMG 409 
during the latter stages of the 60 MVC protocol compared to placebo, which might be linked, 410 
in part, to increased muscle activation and central motor drive, VA was not impacted by 411 
ACT. This might have been a function of the continuous assessment of the EMG response 412 
and torque throughout the 60 MVC protocol, compared to every 6
th
 MVC for VA, such that 413 
EMG might have provided a more complete picture of central fatigue development across the 414 
protocol. Recent research has also challenged the validity of VA estimated using the 415 
interpolated twitch technique as a measure of central fatigue (Neyroud et al. 2016), which 416 
might contribute to the disparity between the EMG-inferred central motor drive and the VA 417 
results. Accordingly, further research is required to resolve the underlying mechanisms for 418 
the ergogenic effect of ACT ingestion. Although the current study is consistent with previous 419 
studies reporting an ergogenic effect of acute ACT consumption (Foster et al. 2014; Mauger 420 
et al. 2010, 2014), we do not advocate regular ACT use or exceeding a single dose of 1 g 421 
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given the potent hepatotoxicity of ACT ingestion (Graham et al. 2013). Therefore, 422 
individuals wishing to explore the use of ACT to enhance exercise performance should do so 423 
infrequently, and with caution.  424 
 425 
In conclusion, acute ACT ingestion increased the mean torque across 60 MVCs of the knee-426 
extensors in agreement with earlier reports that ACT can attenuate neuromuscular fatigue 427 
development and improve exercise performance. Our results extend these previous 428 
observations by providing novel insights into the mechanisms for the potential ergogenic 429 
effect of ACT ingestion.  Specifically, the improved mean torque was accompanied by an 430 
increase in CT and greater muscle activation during the latter stages of the 60 MVC protocol. 431 
Therefore, ACT ingestion appears to attenuate fatigue development during repeated skeletal 432 
muscle MVCs by enabling a better preservation of muscle activation during exercise.  433 
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Legends to figures 586 
Figure 1 587 
Graphic overview of the procedures used in the current study. A and C: Procedures employed 588 
pre and post (<10 s) high-intensity exercise, respectively. 10 s separated each single pulse 589 
stimulation administered at rest (small dashed arrows). A 45 s rest period separated maximal 590 
efforts (MVCs). Single pulse stimuli were administered during peak force production of 591 
MVCs (large solid arrow) and immediately (1-2 s post; small grey arrows). B: 60 MVC 592 
protocol of the knee extensors. The figure presents a period of 30 s which is repeated 593 
sequentially for 5 min. Each MVC was held for 3 s and interspersed by a 2 s passive recovery 594 
period. Every 6
th
 MVC was accompanied by single pulse stimuli administered during peak 595 
force production (Large solid arrow) and immediately following (<2 s post; small grey 596 
arrows). This cycle was repeated 10 times such that the protocol spanned 5 minutes requiring 597 
the completion of 60 MVCs. MVC, maximal voluntary isometric contraction. Surface 598 
electromyography (EMG) was measured throughout. 599 
 600 
Figure 2 601 
Torque profile during the 60 maximal contractions for placebo (clear circles) and 602 
acetaminophen (filled circles) trials. All contractions were normalized to a control maximal 603 
voluntary contraction (MVC) performed before the test commenced. Mean ± SE torque 604 
responses are presented in panel A with the torque response from a representative individual 605 
presented in panel B.  Note that torque falls over the first ~150 s before reaching stable values 606 
between 240 and 300 s (the end-test torque; last 12 MVCs).  607 
 608 
Figure 3 609 
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Individual responses to ACT supplementation on 60 MVC performance (torque-impulse). 610 
*Significantly different from placebo (P<0.05). 611 
 612 
Figure 4 613 
Mean ± SE potentiated twitch (A), voluntary activation (B), and M-wave amplitude (C) 614 
responses during the 60 maximal voluntary contraction (MVC) test for placebo (clear circles) 615 
and acetaminophen (filled circles) trials.  616 
 617 
Figure 5 618 
Surface electromyography (EMG) responses (expressed relative to M-wave amplitude) 619 
during the 60 MVC test for placebo (clear circles) and acetaminophen (filled circles) trials.  620 
Mean ± SE EMG responses are presented in panel A with the EMG response from a 621 
representative individual presented in panel B.  *Significantly different from placebo 622 
(P<0.05).  623 
